ArticleCureus2025
Ovine Forestomach Matrix Graft Reduces Surgical Dehiscence in Fasciocutaneous Flap-Based Closure of Pilonidal Disease: A Comparative Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Safety of Ovine Forestomach Matrix Across 474 Soft Tissue Defects: Interim Results from the Prospective Multicenter MASTRR Registry.Advances in therapy · 2026Article
- Functional soft tissue regeneration involving extremity tendons using ovine forestomach matrix grafts.Journal of surgical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Fasciocutaneous flap advancement is a newer alternative surgical approach in pilonidal sinus disease (PSD). This comparative study aimed to assess whether the use of an ovine forestomach matrix (OFM) graft implanted beneath a fasciocutaneous flap closure could minimize dehiscence complications in PSD. Methods PSD patients who received OFM and a fasciocutaneous flap were prospectively enrolled. Findings were compared to retrospective data from control patients who did not receive an OFM graft. Study outcomes were time to heal, incidence of dehiscence, and scar cosmesis. A within-study cost-utility analysis estimated costs and quality-adjusted life-years (QALYs). Results A total of 46 patients who received a flap advancement and OFM graft were compared to 48 retrospective control patients who were treated with flap advancement alone. No difference in median healing time was found in the OFM group (8.0 (IQR: 4.2, 15.8) weeks) compared to the control group (8.0 (IQR: 6.0, 15.2) weeks) (p=0.79). The incidence of dehiscence was significantly less in the OFM group (18%) versus the control group (46%) (p=0.005). The probability of dehiscence in the control group was 3.2 times greater compared to the OFM group. In a cost-utility analysis, the OFM group dominated the control group, with higher QALYs (0.24 vs. 0.23) and lower costs ($4,157 vs. $4,219). Conclusions The use of OFM graft with a fasciocutaneous flap resulted in a significantly lower incidence of dehiscence and potentially higher quality-of-life and cost savings, while maintaining a midline incision with favorable cosmesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.